07/08/08
After nearly 12 years of research and development, Immunomedicor
begins to further commercialize a novel line
of drugs for various Auto Immune System disorders.
07/23/08
Immunomedicor announces its vision at the first anual Crab Boil
in Washington, DC.
08/23/08
Immunomedicor begins work on business plan
towards funding development of potential drug candidates.
09/07/08
Immunomedicor begins research on the development of IM-039-MAB-CAN,
a non-toxic drug to be used in the treatment of various types of
Cancer.
11/24/08
Immunomedicor public web site goes live.
01/24/09
Immunomedicor ribbon cutting ceremony scheduled to take place on Jan 24,
2009
in Washington, DC.
02/28/09
Immunomedicor releases news update on Immucore molecule
status in public press release and web video.
04/25/09
Immunomedicor releases product information in web video.
07/18/09
Immunomedicor forms strategic alliances with leading biotech
industry and education partners.
07/15/10
Immunomedicor begins next round of fundraising for IM-039-MAB-MML.
John Kruebbe, the new CEO and CTO works to recruit new scientists
to the company.
07/22/10
Immunomedicor recruits a new science advisor to the board
of directors, Chun-Hsien Huang, and initial work begins on patenting
and manufacturing Imucore for further pre-clinical trials.
|